Moseley 1976.

Methods	Randomised Phase II trial
Participants	5 women with squamous cell cervical cancer considered to be unsuitable for surgery. These women were part of a larger trial of 35 patients with squamous cell cancer in a variety of primary sites
Interventions	Arm 1: CCNU (lomustine) 100‐130 mg/m2 po depending on bone marrow reserves d1 plus bleomycin 0.5 mg/kg im or iv d8, 11, 15, 18, 22, 25, 29, 32, 36, 39 q42 days Arm 2: CCNU 100‐130 mg/m2 po depending on bone marrow reserves d1 plus vinblastine 0.1 mg/kg iv d8, 15 plus methotrexate 0.5 mg/kg iv (maximum 25 mg) d8, 15 plus bleomycin 0.5 mg/kg im or iv d8, 15, 18, 22, 25, 29, 32 q56 days Maximum cumulative dose of bleomycin is 300 mg
Outcomes	Response rates Toxicity
Notes	1 patient dropped out after cycle 1 day 1 treatment (single‐dose CCNU) to have treatment elsewhere and was considered unevaluable. No ITT analysis performed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not documented but OS unlikely to be affected by blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	No missing outcome data
Selective reporting (reporting bias)	Low risk	Published report included all pre‐specified outcomes
Other bias	Low risk	No hint at any other possible biases